Discovery of new PKN2 inhibitory chemotypes via QSAR-guided selection of docking-based pharmacophores.

Al-Sha'er, Mahmoud A; Basheer, Haneen A; Taha, Mutasem O

Al-Sha'er, Mahmoud A; Basheer, Haneen A; Taha, Mutasem O.

Affiliation

Al-Sha'er MA; Faculty of Pharmacy, Zarqa University, P.O. Box 132222, Zarqa, 13132, Jordan. a.mahmoud@zu.edu.jo.
Basheer HA; Faculty of Pharmacy, Zarqa University, P.O. Box 132222, Zarqa, 13132, Jordan.
Taha MO; Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Jordan, Amman, Jordan. mutasem@ju.edu.jo.

Mol Divers ; 27(1): 443-462, 2023 Feb.

Article in En | MEDLINE | ID: mdl-35507210

Subject(s)

Neoplasms; Pharmacophore; Protein Kinase C; Protein Kinase Inhibitors; Humans; Ligands; Molecular Docking Simulation; Protein Kinase C/antagonists & inhibitors; Protein Kinase Inhibitors/pharmacology; Quantitative Structure-Activity Relationship; Cell Line, Tumor

Key words

Anticancer; PKN2; QSAR guided selection of pharmacophores; Structure based modeling

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Protein Kinase C / Protein Kinase Inhibitors / Pharmacophore / Neoplasms Type of study: Prognostic_studies Limits: Humans Language: En Year: 2023 Type: Article

Fulltext

XML

PubMed Links

Search on Google